CRL
Charles River Laboratories International, Inc.
NYSE · Healthcare · Medical - Diagnostics & Research · US
$288.87
−1.53%Margins
Gross margin
32.2%
EBITDA margin
5.5%
EBIT margin
12.3%
Net margin
-6.0%
FCF margin
9.3%
-8.4%
Return on equity
-3.2%
Return on assets
8.4%
Return on invested capital
0.52x
Asset turnover
$582.1M
Cash from operations
$4.02
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026